Cancer is one of the leading causes of morbidity and mortality worldwide, but therapeutic innovation has changed the treatment paradigm drastically. Cancer medication demand is increasing due to high unmet medical need and incidence rate. This reflects in growing revenues for pharmaceutical companies operating in this space and increasing investments in oncology R&D. The key factors driving the growth of this pharmaceutical segment are the large number of new compounds with new mechanisms of action and the high cost of these medications.
Luca Dezzani is a Novartis employee. All the views, analysis, and perspectives are fully independent and belongs to the author only. They do not represent the views or opinions of Novartis or any other company or organization. IgeaHub is a pharmaceutical blog created and curated by Luca Dezzani. IgeaHub does not receive any founding or support from Novartis or any other pharmaceutical company.